FDA Updates

Products encompassing newly approved Rx drugs and generics, plus health and beauty care, home health care, and other items.

Organized by HBC category, the never-out list is Hamacher Resource Group's proprietary list of products that pharmacy shelves should never be without. The following is a partial list of never-outs from the weight-control category.

Long-acting levocetirizine (Xyzal, UCB/Sanofi-Aventis) has received regulatory approval for the relief of symptoms associated with seasonal and perennial allergic rhinitis and for uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children six years of age and older.

New immunosuppressive regimens that combine Certican and low-dose Neoral to preverse renal function following heart transplants and Viagra to lower pulmonary arterial heypertension are coming soon to hospitals.

The FDA is advising consumers not to purchase or use True Man and Energy Max products promoted and sold as dietary supplements throughout the U.S. Both products—touted as sexual enhancement aids and treatments for erectile dysfunction (ED)—are illegal products that contain potentially harmful, undeclared ingredients.

Which over-the-counter and health and beauty care brands accounted for the most dollar sales in drugstores, supermarkets, and mass-mercahndisers last year?

What follows is a review of the biggest news of 2006 in just a few categories, along with their new product standouts.

The FDA recommends that you counsel patients on the importance of reading product labels carefully to determine the active ingredients and dosing instructions of each product and to discourage them from making assumptions about use based on product names or appearance. The use of similar trade names (so-called "brand-name families") is common practice for OTC products. The products with the trade names "Sudafed" and "Sudafed PE" illustrate specific concerns.

A group of researchers at the University of Florida College of Pharmacy recently submitted a citizen's petition asking the Food & Drug Administration to increase the maximum allowable dose of phenylephrine (PE) from 10 mg to 25 mg and to withdraw approval of phenylephrine for children under 12 years of age. The petition also called for additional research to validate the safety and effectiveness of the higher recommended dose.

The new guide recommends that physicians start with nonpharmacologic treatments such as exercise, physical therapy, weight loss, and heat or cold therapy. If there is no relief of pain, physicians should consider acetaminophen, aspirin, and even short-term use of narcotic analgesics as a first step, taking the patient's medical history into account.